UniQure slides after mixed data from genetic disease therapy

uniQure

21/06/2023 16:23

(Updates)
    ** U.S.-listed shares  QURE.O  of gene therapy developer
UniQure fall ~41% to more than five-year low of $10.51
    ** Stock among top pct losers across U.S. exchanges 
    ** Netherlands-based company's gene therapy for Huntington's
disease reduced levels of key protein linked to the disease by
8.1% at lower dose vs 52.8% reduction reported by company last
year
    ** Huntington's disease is an inherited disorder which
results in the death of brain cells and is caused by a mutation
in the gene for a protein called huntingtin (HTT)
    ** Stifel analysts say mHTT data very confusing and
discordant with prior 1-year data 
    ** In updated data from an early- to mid-stage trial, QURE
says the gene therapy helped improve motor score and other
measures
    ** UniQure's U.S.-listed shares down 14.3% YTD

 (Reporting by Manas Mishra and Bhanvi Satija)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))